|
|
|
BEAM Forecast
Recent BEAM Price |
|
BEAM Forecast Price |
$21.38 |
+137.37% |
$50.75 |
As of 2024-04-29
Recent BEAM Analyst Ratings Breakdown |
|
Current |
1 Mo. Ago |
2 Mo. Ago |
3 Mo. Ago |
Strong buy ratings: |
8 |
8 |
8 |
7 |
Buy ratings: |
0 |
0 |
0 |
0 |
Hold ratings: |
7 |
7 |
7 |
8 |
Sell ratings: |
0 |
0 |
0 |
0 |
Strong sell ratings: |
0 |
0 |
0 |
0 |
Average rating: |
1.93 |
1.93 |
1.93 |
2.07 |
In the last row of the above table, the average rating presented is from 1 to 5 where 1 means Strong Buy and 5 means Strong Sell.
For the Beam Therapeutics Inc forecast (traded under symbol BEAM) for one year forward price target at the top of this page, we have presented the average BEAM forecast for forward target price across the 12 analysts covering BEAM, as reported in
data provided by Zacks Investment Research via Quandl.com.
Meanwhile, note that the
median BEAM forecast price target (median being the middle where half of analysts had a higher BEAM forecast and half had a lower BEAM forecast, which is a different metric than the average or mean) was $50.0 as of 2024-04-29, while the
highest BEAM forecast in the analyst group was $78.0, and the lowest BEAM forecast in the analyst group was
$27.0, with a standard deviation of $16.815. Get the latest Zacks research report on BEAM — FREE
Dividend Growth Stocks: 25 Aristocrats
10 Dividend Bargains You Can Buy Cheaper Than Insiders Did
Name: |
Beam Therapeutics Inc |
Website: |
www.beamtx.com |
Sector: |
Biotechnology |
Number of ETFs Holding BEAM: |
40 (see which ones) |
Total Market Value Held by ETFs: |
$418,337,532.37 |
Total Market Capitalization: |
$1,857,000,000 |
% of Market Cap. Held by ETFs: |
22.53% |
|
|
|
|
Buy (3.07 out of 4)
39th percentile
|
PARTNER NEWS:Tue, Feb 27, 2:39 PM, Zacks
Brian's Big Idea on Healthcare Big moving drug stocks and the HealthCare Innovators service at Zacks.
Thu, Feb 15, 4:45 AM, Zacks
5 Biotech Stocks Likely to Outpace Q4 Earnings Estimates Let us look at some drug/biotech stocks, MRNA, BMRN, AMRN, NTLA and BEAM, which are poised to beat on fourth-quarter earnings.
|
|